Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

Jacques Delaunay; Grzegorz Mazur; Mark Minden; Agnieszka Wierzbowska; Mark M Jones; Erhan Berrak; Hagop M Kantarjian

doi:10.1016/j.lrr.2013.12.001

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

Leuk Res Rep. 2013 Dec 27;3(1):17-20. doi: 10.1016/j.lrr.2013.12.001. eCollection 2014.

Authors

Jacques Delaunay¹, Grzegorz Mazur², Mark Minden³, Agnieszka Wierzbowska⁴, Mark M Jones⁵, Erhan Berrak⁵, Hagop M Kantarjian⁶

Affiliations

¹ University of Nantes, Nantes, France.
² Wroclaw Medical University, Wroclaw, Poland.
³ Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada.
⁴ Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
⁵ Eisai Corporation, Woodcliff Lake, NJ, USA.
⁶ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Background: In a phase III trial, older patients with acute myeloid leukemia (N=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood cell (WBC) counts predicted response.

Methods: Baseline WBCs and renal and liver function markers were tabulated for responders/nonresponders.

Results: Nonresponders had higher mean baseline creatinine (P=0.005). Creatinine data showed no significant between-group differences by treatment within responder category.

Conclusions: No relationship was found between baseline WBCs or hepatic function and response. Higher baseline creatinine in nonresponders may not be clinically relevant.

Keywords: ALT, alanine aminotransferase; AML, acute myeloid leukemia; AST, aspartate aminotransferase; Acute myeloid leukemia; Adult; BUN, blood urea nitrogen; CR, complete response; CRi, complete response with incomplete blood count recovery; Decitabine; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FAB, French–American–British classification; Leukemia; PR, partial remission; Prognosis; SC, supportive care; WBC, white blood cell.